Migraine sufferers rate new drug in gulf study
NCT ID NCT06237062
First seen Nov 20, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This study followed 37 adults with migraine who had just started taking erenumab. Over 12 weeks, researchers measured how satisfied patients were with the treatment using a questionnaire. The goal was to see if erenumab improved their experience and symptom control in everyday life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.